disulfiram has been researched along with dacarbazine in 16 studies
| Timeframe | Studies, this research(%) | All Research% |
|---|---|---|
| pre-1990 | 0 (0.00) | 18.7374 |
| 1990's | 0 (0.00) | 18.2507 |
| 2000's | 2 (12.50) | 29.6817 |
| 2010's | 14 (87.50) | 24.3611 |
| 2020's | 0 (0.00) | 2.80 |
| Authors | Studies |
|---|---|
| González-Díaz, H; Orallo, F; Quezada, E; Santana, L; Uriarte, E; Viña, D; Yáñez, M | 1 |
| Barnes, JC; Bradley, P; Day, NC; Fourches, D; Reed, JZ; Tropsha, A | 1 |
| Ekins, S; Williams, AJ; Xu, JJ | 1 |
| Chen, M; Fang, H; Liu, Z; Shi, Q; Tong, W; Vijay, V | 1 |
| Ambroso, JL; Ayrton, AD; Baines, IA; Bloomer, JC; Chen, L; Clarke, SE; Ellens, HM; Harrell, AW; Lovatt, CA; Reese, MJ; Sakatis, MZ; Taylor, MA; Yang, EY | 1 |
| Cantin, LD; Chen, H; Kenna, JG; Noeske, T; Stahl, S; Walker, CL; Warner, DJ | 1 |
| Afshari, CA; Chen, Y; Dunn, RT; Hamadeh, HK; Kalanzi, J; Kalyanaraman, N; Morgan, RE; van Staden, CJ | 1 |
| Chen, M; Hu, C; Suzuki, A; Thakkar, S; Tong, W; Yu, K | 1 |
| Doñate, F; Fruehauf, JP; Lee, K; Mazar, AP; Trapp, V | 1 |
| Berns, R; Dunn, SE; Fotovati, A; Hu, K; Kast, RE; Kong, E; Lee, C; Luk, M; Pambid, M; Toyota, B; Toyota, E; Triscott, J; Yip, S | 1 |
| Boockvar, JA; Brüning, A; Cappello, F; Chang, WW; Cvek, B; Dou, QP; Duenas-Gonzalez, A; Efferth, T; Focosi, D; Ghaffari, SH; Halatsch, ME; Karpel-Massler, G; Kast, RE; Keizman, D; Ketola, K; Khoshnevisan, A; Magné, N; Marosi, C; McDonald, K; Muñoz, M; Paranjpe, A; Pourgholami, MH; Sardi, I; Sella, A; Srivenugopal, KS; Tuccori, M; Wang, W; Wirtz, CR | 1 |
| Halatsch, ME; Karpel-Massler, G; Kast, RE | 1 |
| Chen, W; Fan, B; Li, T; Xiao, Z; Yang, J; Zhao, Y | 1 |
| Kast, RE | 1 |
| Campian, JL; DeWees, TA; Gujar, AD; Huang, J; Kim, AH; Lockhart, AC; Tran, DD; Tsien, CI | 1 |
| Aman, A; Cairncross, JG; Dang, NH; Datti, A; Easaw, JC; Grinshtein, N; Hao, X; Kaplan, DR; King, JC; Luchman, A; Lun, X; Robbins, SM; Senger, DL; Uehling, D; Wang, X; Weiss, S; Wells, JC; Wrana, JL | 1 |
2 review(s) available for disulfiram and dacarbazine
| Article | Year |
|---|---|
DILIrank: the largest reference drug list ranked by the risk for developing drug-induced liver injury in humans.
Topics: Chemical and Drug Induced Liver Injury; Databases, Factual; Drug Labeling; Humans; Pharmaceutical Preparations; Risk | 2016 |
A conceptually new treatment approach for relapsed glioblastoma: coordinated undermining of survival paths with nine repurposed drugs (CUSP9) by the International Initiative for Accelerated Improvement of Glioblastoma Care.
Topics: Antineoplastic Combined Chemotherapy Protocols; Aprepitant; Artemisinins; Auranofin; Brain Neoplasms; Captopril; Dacarbazine; Disulfiram; Glioblastoma; Gluconates; Humans; Ketoconazole; Morpholines; Nelfinavir; Neoplasm Recurrence, Local; Sertraline; Succinates; Temozolomide | 2013 |
1 trial(s) available for disulfiram and dacarbazine
| Article | Year |
|---|---|
A phase I study to repurpose disulfiram in combination with temozolomide to treat newly diagnosed glioblastoma after chemoradiotherapy.
Topics: Administration, Oral; Adult; Aged; Antineoplastic Agents; Chemoradiotherapy; Dacarbazine; Disulfiram; Dose-Response Relationship, Drug; Drug Repositioning; Drug Therapy, Combination; Female; Glioblastoma; Humans; Male; Middle Aged; Proteasome Endopeptidase Complex; Proteasome Inhibitors; Supratentorial Neoplasms; Temozolomide; Treatment Outcome; Young Adult | 2016 |
13 other study(ies) available for disulfiram and dacarbazine
| Article | Year |
|---|---|
Quantitative structure-activity relationship and complex network approach to monoamine oxidase A and B inhibitors.
Topics: Computational Biology; Drug Design; Humans; Isoenzymes; Molecular Structure; Monoamine Oxidase; Monoamine Oxidase Inhibitors; Quantitative Structure-Activity Relationship | 2008 |
Cheminformatics analysis of assertions mined from literature that describe drug-induced liver injury in different species.
Topics: Animals; Chemical and Drug Induced Liver Injury; Cluster Analysis; Databases, Factual; Humans; MEDLINE; Mice; Models, Chemical; Molecular Conformation; Quantitative Structure-Activity Relationship | 2010 |
A predictive ligand-based Bayesian model for human drug-induced liver injury.
Topics: Bayes Theorem; Chemical and Drug Induced Liver Injury; Humans; Ligands | 2010 |
FDA-approved drug labeling for the study of drug-induced liver injury.
Topics: Animals; Benchmarking; Biomarkers, Pharmacological; Chemical and Drug Induced Liver Injury; Drug Design; Drug Labeling; Drug-Related Side Effects and Adverse Reactions; Humans; Pharmaceutical Preparations; Reproducibility of Results; United States; United States Food and Drug Administration | 2011 |
Preclinical strategy to reduce clinical hepatotoxicity using in vitro bioactivation data for >200 compounds.
Topics: Chemical and Drug Induced Liver Injury; Cytochrome P-450 Enzyme Inhibitors; Cytochrome P-450 Enzyme System; Decision Trees; Drug Evaluation, Preclinical; Drug-Related Side Effects and Adverse Reactions; Glutathione; Humans; Liver; Pharmaceutical Preparations; Protein Binding | 2012 |
Mitigating the inhibition of human bile salt export pump by drugs: opportunities provided by physicochemical property modulation, in silico modeling, and structural modification.
Topics: Animals; ATP Binding Cassette Transporter, Subfamily B, Member 11; ATP-Binding Cassette Transporters; Bile Acids and Salts; Cell Line; Chemical and Drug Induced Liver Injury; Humans; Quantitative Structure-Activity Relationship | 2012 |
A multifactorial approach to hepatobiliary transporter assessment enables improved therapeutic compound development.
Topics: Animals; ATP Binding Cassette Transporter, Subfamily B; ATP Binding Cassette Transporter, Subfamily B, Member 11; ATP-Binding Cassette Transporters; Biological Transport; Chemical and Drug Induced Liver Injury; Cluster Analysis; Drug-Related Side Effects and Adverse Reactions; Humans; Liver; Male; Multidrug Resistance-Associated Proteins; Pharmacokinetics; Rats; Rats, Sprague-Dawley; Recombinant Proteins; Risk Assessment; Risk Factors; Toxicity Tests | 2013 |
Redox-related antimelanoma activity of ATN-224.
Topics: Antineoplastic Agents; Apoptosis; Arsenic Trioxide; Arsenicals; Buthionine Sulfoximine; Cell Line, Tumor; Cell Proliferation; Dacarbazine; Disulfiram; Drug Synergism; Enzyme Inhibitors; Glutathione; Humans; Melanins; Melanoma; Molybdenum; Oxidation-Reduction; Oxides; Reactive Oxygen Species; Superoxide Dismutase; Temozolomide | 2009 |
Disulfiram, a drug widely used to control alcoholism, suppresses the self-renewal of glioblastoma and over-rides resistance to temozolomide.
Topics: Alcohol Deterrents; Antineoplastic Agents, Alkylating; Apoptosis; Blotting, Western; Brain Neoplasms; Cell Line, Tumor; Cell Proliferation; Dacarbazine; Disulfiram; Drug Resistance, Neoplasm; Glioblastoma; Humans; Immunoenzyme Techniques; Temozolomide | 2012 |
CUSP9* treatment protocol for recurrent glioblastoma: aprepitant, artesunate, auranofin, captopril, celecoxib, disulfiram, itraconazole, ritonavir, sertraline augmenting continuous low dose temozolomide.
Topics: Animals; Antineoplastic Combined Chemotherapy Protocols; Aprepitant; Artemisinins; Artesunate; Auranofin; Brain Neoplasms; Captopril; Celecoxib; Dacarbazine; Disulfiram; Glioblastoma; Humans; Itraconazole; Molecular Targeted Therapy; Morpholines; Neoplasm Recurrence, Local; Pyrazoles; Ritonavir; Sertraline; Signal Transduction; Sulfonamides; Temozolomide; Treatment Outcome | 2014 |
Disulfiram sensitizes pituitary adenoma cells to temozolomide by regulating O6-methylguanine-DNA methyltransferase expression.
Topics: AC133 Antigen; Acetaldehyde Dehydrogenase Inhibitors; Adenoma; Animals; Antigens, CD; Antineoplastic Agents, Alkylating; Bortezomib; Cell Survival; Dacarbazine; Disulfiram; DNA Modification Methylases; DNA Repair Enzymes; Drug Resistance, Neoplasm; Drug Synergism; Gene Expression Regulation, Neoplastic; Glycoproteins; Humans; Mice; Mice, Inbred BALB C; Mice, Nude; Nestin; Peptides; Pituitary Neoplasms; Primary Cell Culture; Proteasome Inhibitors; Proteolysis; Temozolomide; Tumor Cells, Cultured; Tumor Suppressor Proteins; Ubiquitination; Xenograft Model Antitumor Assays | 2015 |
The role of interleukin-18 in glioblastoma pathology implies therapeutic potential of two old drugs-disulfiram and ritonavir.
Topics: Antineoplastic Agents; Dacarbazine; Disulfiram; Glioblastoma; Humans; Interleukin-18; Ritonavir; Temozolomide | 2015 |
Disulfiram when Combined with Copper Enhances the Therapeutic Effects of Temozolomide for the Treatment of Glioblastoma.
Topics: Animals; Antineoplastic Agents; Cell Proliferation; Cell Survival; Copper; Dacarbazine; Disease Models, Animal; Disulfiram; DNA Repair; Drug Resistance, Neoplasm; Drug Screening Assays, Antitumor; Drug Synergism; Female; Gene Expression Profiling; Glioblastoma; High-Throughput Screening Assays; Humans; Mice; Neoplastic Stem Cells; Proteasome Endopeptidase Complex; Temozolomide; Tumor Burden; Xenograft Model Antitumor Assays | 2016 |